CAMP - CAMP4 THERAPEUTICS CORPORATION logo

CAMP4 THERAPEUTICS CORPORATION

CAMP
Revenue grew 100% of years1Y
Compare CAMP Hold

Camp4 Therapeutics Corporation develops RNA-based therapeutics targeting genetic diseases, focusing on central nervous system and liver disorders. Its lead candidates include CMP-001 for urea cycle disorders and CMP-002 for SYNGAP1-related conditions.

โš•๏ธ Healthcare NASDAQ Listed 2024 $ USD
$1,000 invested 1 year ago โ†’$1,018today

Score Overview

1 Year
Scoreโ€”
Net Growth-33.38%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth20.53%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-107.07%
Net TrendNever
Net Income Consistencyโ€”
Rev Growth6x
Rev TrendEvery year
Revenue Consistencyโ€”

Explore the 2021 public Archive ranking โ†’

Where CAMP4 THERAPEUTICS CORPORATION has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CAMP does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 3.39โ€”
1 Year2025-10-22
$ 3.331.80%
All Time2024-10-11
$ 10.72-68.38%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 4M-$ 107M$ 86M
2025$ 3M-$ 80M$ 109M
IPO2024$ 652K-$ 51M$ 64M

Membership

Explore CAMP with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies